GcMAF in Autoimmune Diseases
Rebalancing immune dysregulation at its source
Autoimmune diseases arise when the immune system misidentifies healthy tissue as foreign. GcMAF's immunomodulatory properties have been studied in conditions such as rheumatoid arthritis, lupus, multiple sclerosis, Hashimoto's thyroiditis, and inflammatory bowel disease. Rather than broad immunosuppression, GcMAF may support the restoration of immune tolerance through macrophage regulation.
Key Findings
- Research suggests GcMAF may modulate Th1/Th2 cytokine balance
- Studies explore potential reduction in autoantibody activity
- Macrophage-mediated regulatory pathways identified in autoimmune models
- Published reports on use in lupus, RA, and MS patient populations
Mechanism of Action
By activating macrophages and supporting regulatory T-cell interactions, GcMAF may help restore the immune system's ability to distinguish self from non-self, potentially reducing inappropriate inflammatory responses characteristic of autoimmune disease.
Clinical Notes
Autoimmune applications require careful clinical monitoring. GcMAF should not be initiated without thorough immune profiling and specialist oversight.
Interested in GcMAF for Your Clinic?
Contact our medical team to discuss clinical applications and procurement.
Next Application
Chronic Infections